Immortalized Clonal MSC Line for Standardized Exosome Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies face challenges such as tumor formation, limited therapeutic efficacy, and heterogeneity in mesenchymal stem cells (MSCs), making it difficult to produce a consistent and standardized fraction of therapeutically active MSC-derived exosomes for clinical applications, particularly in treating conditions like perinatal brain injury.
Innovation Solution
A method is developed to produce a clonal mesenchymal stem cell line from human induced pluripotent stem cells (hiPSCs), which are immortalized and characterized for their ability to produce exosomes, ensuring a consistent and reproducible source of therapeutically active MSC-derived extracellular vesicles (EVs) using xeno-free and serum-free conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cells are isolated and cultured for therapy, then therapeutic application is enabled, but tumor formation and immune reactions occur
Solution Approach 1:
The patent extracts and utilizes only the therapeutic components (exosomes) from stem cells, rather than transplanting entire stem cells. This is achieved through isolating exosomes secreted by hiPSC-derived MSCs, which carry therapeutic factors without the risks associated with live cell transplantation such as tumor formation and immune rejection
Solution Approach 2:
The patent uses exosomes as an intermediary carrier to deliver therapeutic factors to target tissues. Instead of directly transplanting stem cells that may cause harm, the exosomes serve as safe mediators that transport bioactive molecules (proteins, lipids, nucleic acids) to exert therapeutic effects without the risks of cell-based therapy
2Reliability
If mesenchymal stem cells are used for therapy, then regenerative effects are achieved, but heterogeneity prevents standardized production
Solution Approach 1:
The patent segments the heterogeneous MSC population into individual clonal lines, each with uniform characteristics. By isolating single MSC clones and expanding them, the method ensures genetic and functional homogeneity, enabling standardized production while maintaining regenerative efficacy
Solution Approach 2:
The patent changes the source and cultivation parameters of MSCs by deriving them from hiPSCs under defined xeno-free and serum-free conditions. This standardization of cellular source and culture parameters ensures consistent quality and therapeutic activity across batches, overcoming the heterogeneity issue
3Reliability
If stem cell therapy is applied clinically, then treatment outcomes are sought, but distinct therapeutic effects are not exhibited
Solution Approach 1:
The patent implements quality control feedback mechanisms by characterizing exosome preparations for purity, concentration, and bioactivity before clinical use. This ensures that only therapeutically active exosomes are administered, enabling measurable and distinct therapeutic effects through standardized quality assurance
Data Source
AI summary
The invention relates to a method of producing a clonal mesenchymal stem cell line capable of producing exosomes (MSC-derived extracellular vesicles) comprising the steps of, providing human induced pluripotent stem cells (hiPSCs), generating therefrom an immortalized clonal cell line of mesenchymal stem cells (IMSC), optionally characterizing the potential of the IMSCs to produce exosomes. The invention also relates to a stem cell line produced according to the invention. The invention relates to the cell line according to the invention, for use as a medicament. The invention relates to the cell line according to the invention for use in treating a disease that is amenable to treatment with stem cell therapy. The invention also relates to the use of a stem cell line according to the invention for producing EVs.